Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | CNR2 | P34972 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicatechin Gallate SCHEMBL30977096 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39046 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| (-)-Catechingallate SCHEMBL31181360 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL39047 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL4639313 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL13014548 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Catechin Gallate SCHEMBL145289 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL4545330 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL8426343 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA | |
| Epicatechin Gallate SCHEMBL31297152 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1BCL2PSMB5SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122042866-A | Method for separating, detecting and identifying flavonoid component in cocoa | 中国热带农业科学院香料饮料研究所 | 2026-05-15 | — | — | CN | claimed |
| EP-4622629-A1 | METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | Caliway Biopharmaceuticals Co. Ltd. (TW) | 2025-10-01 | — | — | EP | claimed |
| EP-3381451-B1 | PHARMACEUTICAL COMPOSITION USED FOR REDUCING LOCALISED FAT AND USE OF PHARMACEUTICAL COMPOSITION | CALIWAY BIOPHARMACEUTICALS CO LTD (TW) | 2025-08-20 | — | — | EP | claimed |
| US-20250041375-A1 | SUGAR CANE EXTRACTS FOR USE IN ANIMAL FEEDS | Poly Gain Pte Ltd (SG) | 2025-02-06 | — | — | US | claimed |
| US-20240358740-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | CROSS III WILLIAM H (US) | 2024-10-31 | — | — | US | claimed |
| US-20240350574-A1 | PHENOLIC PHYTOCHEMICALS FOR BONE METASTASIS OF CANCER | NDSU RESEARCH FOUNDATION | 2024-10-24 | — | — | US | claimed |
| CN-118581042-A | NK cell culture system and method for in vitro culture of NK cells | 深圳市济因生物科技有限公司 | 2024-09-03 | — | — | CN | claimed |
| EP-4408480-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2024-08-07 | — | — | EP | claimed |
| US-12029750-B2 | Folic compositions and methods for treatment of diabetic neuropathies | CROSS III WILLIAM H (US) | 2024-07-09 | — | — | US | claimed |
| WO-2024109276-A1 | METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY | CALIWAY BIOPHARMACEUTICALS CO., LTD. (CN) | 2024-05-30 | — | — | WO | claimed |
| EP-4188408-A1 | A STANDARDIZED BIOFLAVONOID COMPOSITION FOR REGULATION OF HOMEOSTASIS OF HOST DEFENSE MECHANISM | Unigen, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| EP-3378506-B1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230157342-A1 | TASTE OF CONSUMABLES | THE PRODUCT MAKERS (AUSTRALIA) PTY LTD (AU) | 2023-05-25 | — | — | US | claimed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | claimed |
| CN-115902030-A | Method for identifying natural fruit juice based on 9 phenolic compounds | 宝健（北京）生物技术有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-110801445-B | Composition containing benzo-hydropyranol derivative and emodin type anthraquinone compound, and dosage form and application thereof | 中山万远新药研发有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-110859830-B | Composition containing benzo-hydropyranol derivative and alizarin type anthraquinone compound, and dosage form and application thereof | 中山万远新药研发有限公司 | 2023-03-21 | — | — | CN | claimed |
| US-20220305047-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | CROSS III WILLIAM H (US) | 2022-09-29 | — | — | US | claimed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | claimed |
| EP-3463276-B1 | PROCESS FOR TREATING HAIR | KAO GERMANY GMBH (DE) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | DYRK1A 3665/4885BACE1 3367/4885BCL2 2321/4885 |
| US-12029750-B2 | Folic compositions and methods for treatment of diabetic neuropathies | FOLR2, FPGS, DHFR | DYRK1A 558/4885BACE1 2387/4885BCL2 618/4885 |
| US-20240358740-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | FOLR2, FPGS, DHFR | DYRK1A 558/4885BACE1 2387/4885BCL2 618/4885 |
| US-20220305047-A1 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | FOLR2, FPGS, DHFR | DYRK1A 558/4885BACE1 2387/4885BCL2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.